Intrinsic Therapeutics Launches Innovative Barricaid Narrow Anchor to Minimize Reherniation Risks Post Back Surgery Intrinsic Therapeutics has unveiled the Barricaid® Narrow Anchor, a groundbreaking device aimed at mitigating reherniation following back surgery. The new design enhances safety and efficiency.

Intrinsic Therapeutics Launches Innovative Barricaid Narrow Anchor to Minimize Reherniation Risks Post Back Surgery #USA #Boston #Intrinsic_Therapeutics #Barricaid #Back_Surgery

Intrinsic Therapeutics Completes First Endoscopic Barricaid Implantation in Great Lakes Region Intrinsic Therapeutics marks a milestone with the first endoscopic Barricaid implantation in the Great Lakes region by Dr. Nick Nenadovich, enhancing treatment options for disc herniations.

Intrinsic Therapeutics Completes First Endoscopic Barricaid Implantation in Great Lakes Region #United_States #Chicago #Intrinsic_Therapeutics #Barricaid #Nick_Nenadovich

Intrinsic Therapeutics Announces CPT Code for Innovative Annular Closure Device Effective 2026 Intrinsic Therapeutics reveals the introduction of a new CPT code for Barricaid, aimed at enhancing patient care for discectomy procedures beginning January 1, 2026.

Intrinsic Therapeutics Announces CPT Code for Innovative Annular Closure Device Effective 2026 #United_States #Boston #Barricaid #Annular_Closure #CPT_Code

Intrinsic Therapeutics Achieves First Awake Implantation of Barricaid Annular Closure Device Intrinsic Therapeutics has successfully implanted the Barricaid device in patients under awake sedation for the first time, enhancing recovery and minimizing reherniation risks.

Intrinsic Therapeutics Achieves First Awake Implantation of Barricaid Annular Closure Device #United_States #Vail #Intrinsic_Therapeutics #Barricaid #Dr._Braxton

Intrinsic Therapeutics Strengthens Leadership with New Sales Executives to Transform Discectomy Treatment Intrinsic Therapeutics has appointed Mike Lytle and Dave Decker as VPs of Sales, aiming to enhance sales and advance their innovative discectomy treatment.

Intrinsic Therapeutics Strengthens Leadership with New Sales Executives to Transform Discectomy Treatment #USA #Boston #medical_technology #Intrinsic_Therapeutics #Barricaid

Intrinsic Therapeutics Innovates with Endoscopic Barricaid® Implantation for Lumbar Discectomy Intrinsic Therapeutics has successfully conducted the first endoscopic implantation of the Barricaid® device, a major advancement for lumbar discectomy patients.

Intrinsic Therapeutics Innovates with Endoscopic Barricaid® Implantation for Lumbar Discectomy #USA #New_York #Intrinsic_Therapeutics #Barricaid #Amplify_Surgical

Intrinsic Therapeutics Announces Updated Recommendations for Barricaid Technology to Prevent Reherniation Intrinsic Therapeutics has announced new guidelines from ISASS regarding its innovative Barricaid device aimed at preventing reherniation after lumbar discectomy surgeries.

Intrinsic Therapeutics Announces Updated Recommendations for Barricaid Technology to Prevent Reherniation #United_States #Boston #Intrinsic_Therapeutics #Barricaid #ISASS

Keith Valentine Takes the Helm as New CEO of Intrinsic Therapeutics Intrinsic Therapeutics has appointed Keith Valentine as its new President and CEO, marking a significant shift in leadership aimed at transforming spine care.

Keith Valentine Takes the Helm as New CEO of Intrinsic Therapeutics #USA #Boston #Intrinsic_Therapeutics #Barricaid #Keith_Valentine